Physician profile
Robert W Cary
NPI 1699742106
$11,498.50
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,152 · 2020: $1,594 · 2021: $2,041 · 2022: $3,070 · 2023: $2,400 · 2024: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.15 |
| Education | $130.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,799.89 | 2019-2024 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,168.08 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,008.81 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $959.58 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $832.82 | 2020-2023 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $802.32 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $680.16 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Lilly USA, LLC | $558.26 | 2019-2024 | Emgality, Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $349.17 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Janssen Pharmaceuticals, INC | $317.96 | 2019-2022 | |
| Astellas Pharma US INC | $284.97 | 2023-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $284.37 | 2019-2022 | |
| Allergan, INC. | $270.23 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $249.52 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $227.37 | 2019-2023 | Rexulti |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.